相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Economic Burden of Bladder Cancer Across the European Union
Jose Leal et al.
EUROPEAN UROLOGY (2016)
Price, value, and the cost of cancer drugs
Tito Fojo et al.
LANCET ONCOLOGY (2016)
Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study
Sabine Vogler et al.
LANCET ONCOLOGY (2016)
Actual costs of cancer drugs in 15 European countries
Wim H. van Harten et al.
LANCET ONCOLOGY (2016)
Putting a price on cancer
Richard Sullivan et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Propaganda or the cost of innovation? Challenging the high price of new drugs
Narcyz Ghinea et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Propaganda or the cost of innovation? Challenging the high price of new drugs
Narcyz Ghinea et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)
N. I. Cherny et al.
ANNALS OF ONCOLOGY (2015)
The Ethics and Economics of Pharmaceutical Pricing
Sara Parker-Lue et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 55 (2015)
Development and economic trends in cancer therapeutic drugs: a 5-year update 2010-2014
P. Savage et al.
BRITISH JOURNAL OF CANCER (2015)
Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs
Sham Mailankody et al.
JAMA ONCOLOGY (2015)
VALUE-BASED DIFFERENTIAL PRICING: EFFICIENT PRICES FOR DRUGS IN A GLOBAL CONTEXT
Patricia Danzon et al.
HEALTH ECONOMICS (2015)
Insights into European Drug Shortages: A Survey of Hospital Pharmacists
Kim Pauwels et al.
PLOS ONE (2015)
Convergence of decision rules for value-based pricing of new innovative drugs
Afschin Gandjour
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2015)
Pricing in the Market for Anticancer Drugs
David H. Howard et al.
JOURNAL OF ECONOMIC PERSPECTIVES (2015)
Drug shortages in European countries: a trade-off between market attractiveness and cost containment?
Kim Pauwels et al.
BMC HEALTH SERVICES RESEARCH (2014)
Comparative cancer survival in European countries
Alastair J. Munro
BRITISH MEDICAL BULLETIN (2014)
The political origins of health inequity: prospects for change
Ole Petter Ottersen et al.
LANCET (2014)
Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5-a population-based study
Roberta De Angelis et al.
LANCET ONCOLOGY (2014)
Patent wars: affordable medicines versus intellectual property rights
Jacqui Wise
BMJ-BRITISH MEDICAL JOURNAL (2014)
Bridging the Gap Between Financial Distress and Available Resources for Patients With Cancer: A Qualitative Study
Sophia K. Smith et al.
JOURNAL OF ONCOLOGY PRACTICE (2014)
Current Status and Trends in Performance-Based Risk-Sharing Arrangements Between Healthcare Payers and Medical Product Manufacturers
Josh J. Carlson et al.
APPLIED HEALTH ECONOMICS AND HEALTH POLICY (2014)
The Global Opioid Policy Initiative (GOPI) project to evaluate the availability and accessibility of opioids for the management of cancer pain in Africa, Asia, Latin America and the Caribbean, and the Middle East: introduction and methodology Introduction
N. I. Cherny et al.
ANNALS OF ONCOLOGY (2013)
The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts
Camille Abboud et al.
BLOOD (2013)
Cancer Drug Prices and the Free-Market Forces
Hagop Kantarjian et al.
CANCER (2013)
Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
J. Ferlay et al.
EUROPEAN JOURNAL OF CANCER (2013)
Access to medicines from a health system perspective
Maryam Bigdeli et al.
HEALTH POLICY AND PLANNING (2013)
The Just Price of Cancer Drugs and the Growing Cost of Cancer Care: Oncologists Need to Be Part of the Solution
David G. Pfister
JOURNAL OF CLINICAL ONCOLOGY (2013)
Cancer Drugs in the United States: Justum Pretium-The Just Price
Hagop M. Kantarjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Corruption of Pharmaceutical Markets: Addressing the Misalignment of Financial Incentives and Public Health
Marc-Andre Gagnon
JOURNAL OF LAW MEDICINE & ETHICS (2013)
Financial crisis, austerity, and health in Europe
Marina Karanikolos et al.
LANCET (2013)
Economic burden of cancer across the European Union: a population-based cost analysis
Ramon Luengo-Fernandez et al.
LANCET ONCOLOGY (2013)
Access to cancer medications in low- and middle-income countries
Gilberto de Lima Lopes et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
The Financial Toxicity of Cancer Treatment: A Pilot Study Assessing Out-of-Pocket Expenses and the Insured Cancer Patient's Experience
S. Yousuf Zafar et al.
ONCOLOGIST (2013)
Value based pricing: can it work?
James Raftery
BMJ-BRITISH MEDICAL JOURNAL (2013)
Differential pricing of new pharmaceuticals in lower income European countries
Zoltan Kalo et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2013)
Understanding the components of pharmaceutical expenditure-overview of pharmaceutical policies influencing expenditure across European countries
Sabine Vogler et al.
GABI JOURNAL-GENERICS AND BIOSIMILARS INITIATIVE JOURNAL (2013)
International variability in the reimbursement of cancer drugs by publically funded drug programs
P. K. Cheema et al.
CURRENT ONCOLOGY (2012)
Trends in Compulsory Licensing of Pharmaceuticals Since the Doha Declaration: A Database Analysis
Reed Beall et al.
PLOS MEDICINE (2012)
Determining the Value of Drugs - The Evolving British Experience
Ruth R. Faden et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
The effects of drug market regulation on pharmaceutical prices in Europe: overview and evidence from the market of ACE inhibitors
Fritz von der Schulenburg et al.
HEALTH ECONOMICS REVIEW (2011)
Determinants of branded prescription medicine prices in OECD countries
Panos G. Kanavos et al.
HEALTH ECONOMICS POLICY AND LAW (2011)
Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Europe: a report from the ESMO/EAPC Opioid Policy Initiative
N. I. Cherny et al.
ANNALS OF ONCOLOGY (2010)
Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers
Josh J. Carlson et al.
HEALTH POLICY (2010)
Efficacy Does Not Necessarily Translate to Cost Effectiveness: A Case Study in the Challenges Associated With 21st-Century Cancer Drug Pricing
Bruce E. Hillner et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
分享论文
